 |
The Journal of Neuroscience, May 3, 2006, 26(18):4930-4939; doi:10.1523/JNEUROSCI.5480-05.2006
Previous Article | Next Article 
Neurobiology of Disease
Induction of Glial Fibrillary Acidic Protein Expression in Astrocytes by Nitric Oxide
Saurav Brahmachari,
Yiu K. Fung, and
Kalipada Pahan
Section of Neuroscience, Department of Oral Biology, University of Nebraska Medical Center, Lincoln, Nebraska 68583
Correspondence should be addressed to Dr. Kalipada Pahan, Section of Neuroscience, Department of Oral Biology, University of Nebraska Medical Center, 40th and Holdrege, Lincoln, NE 68583-0740. Email: kpahan{at}unmc.edu
Increased expression of glial fibrillary acidic protein (GFAP) represents astroglial activation and gliosis during neurodegeneration. However, the molecular mechanism behind increased expression of GFAP in astrocytes is poorly understood. The present study was undertaken to explore the role of nitric oxide (NO) in the expression of GFAP. Bacterial lipopolysachharides (LPSs) induced the production of NO and the expression of GFAP in mouse primary astrocytes. Either a scavenger of NO [2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO)] or an inhibitor of inducible nitric oxide synthase [L-N6-(I-iminoethyl)-lysine hydrochloride] blocked this induction of GFAP expression. Similarly, other inducers of NO production such as interferon- , interleukin-1 , human immunodeficiency virus type 1 gp120, fibrillar amyloid peptides, and double-stranded RNA (polyinosinic-polycytidilic acid) also induced the expression of GFAP through NO. The role of NO in the expression of GFAP was supported further by increased expression of GFAP by S-nitroso glutathione (GSNO), an NO donor. Interestingly, inhibition of nuclear factor B (NF- B) suppressed LPS- but not GSNO-induced expression of GFAP, suggesting that NO does not require NF- B to induce GFAP and that NF- B functions upstream of NO production. However, inhibition of LPS- and GSNO-induced expression of GFAP either by NS-2028 [a specific inhibitor of guanylate cyclase (GC)] or by KT5823 [a specific inhibitor of cGMP-activated protein kinase (PKG)], and induction of GFAP expression by either 8-Br cGMP (a cell-permeable cGMP analog) or MY-5445 (a specific inhibitor of cGMP phosphodiesterase) suggests that NO induces GFAP via GC-cGMP-PKG. This study illustrates a novel biological role of NO in regulating the expression of GFAP in astrocytes through the GC-cGMP-PKG pathway that may participate in the pathogenesis of neurodegenerative disorders.
Key words: neurotoxins; nitric oxide; astroglial activation; GFAP; guanylate cyclase; cGMP
Received Aug. 11, 2005;
revised March 21, 2006;
accepted March 25, 2006.
Correspondence should be addressed to Dr. Kalipada Pahan, Section of Neuroscience, Department of Oral Biology, University of Nebraska Medical Center, 40th and Holdrege, Lincoln, NE 68583-0740. Email: kpahan{at}unmc.edu
This article has been cited by other articles:

|
 |

|
 |
 
A. Ghosh, A. Roy, X. Liu, J. H. Kordower, E. J. Mufson, D. M. Hartley, S. Ghosh, R. L. Mosley, H. E. Gendelman, and K. Pahan
Selective inhibition of NF-{kappa}B activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease
PNAS,
November 20, 2007;
104(47):
18754 - 18759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Guo, H. Wang, M. Watanabe, K. Shimizu, S. Zou, S. C. LaGraize, F. Wei, R. Dubner, and K. Ren
Glial-Cytokine-Neuronal Interactions Underlying the Mechanisms of Persistent Pain
J. Neurosci.,
May 30, 2007;
27(22):
6006 - 6018.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|